북미 림프부종 치료 시장 – 2029년까지의 산업 동향 및 예측

북미 림프부종 치료 시장 분석 및 통찰력

림프부종은 일반적으로 팔이나 다리 중 하나에 영향을 미칩니다. 어떤 경우에는 팔과 다리가 모두 영향을 받을 수 있습니다. 어떤 환자는 머리, 생식기 또는 가슴이 부어오르는 것을 경험할 수 있습니다.

림프부종은 치료할 수 없지만, 적절한 치료를 통해 조절이 가능하며, 적절한 치료는 붓기와 통증을 줄이는 데 도움이 될 수 있습니다.

복합적 충혈 완화 요법(CDT): 이는 집중적 치료 단계로 시작하며, 이 기간 동안 환자는 매일 치료와 훈련을 받습니다. 그 다음에는 환자가 배운 기술을 사용하여 치료를 맡도록 격려하는 유지 단계가 이어집니다.

돌연변이는 림프계 발달에 관여하는 일부 유전자에서 원발성 림프부종을 일으킬 수 있습니다. 이러한 결함 있는 유전자는 림프계의 발달을 방해하여 체액을 적절히 배출하는 능력을 약화시킵니다.

2차 림프부종에는 암 수술, 방사선 치료, 감염, 염증 상태, 심혈관 질환, 부상 및 외상을 포함한 여러 가지 원인이 있을 수 있습니다.

암 유병률 증가와 의료비 증가로 인해 의료 시설에서 림프부종을 치료해야 할 필요성이 가속화되었습니다. 혁신과 기술의 급증도 시장 성장을 촉진하고 있습니다.

북미 림프부종 치료 시장은 시장의 떠오르는 플레이어와 고급 영상 제품의 가용성으로 인해 예측 연도에 성장하고 있습니다. 이와 함께 제조업체는 시장에 새로운 제품을 출시하기 위한 R&D 활동에 참여하고 있습니다.

전 세계적으로 암 관련 림프부종 환자의 증가와 R&D 활동의 증가는 예측 기간 동안 북미 림프부종 치료 시장에 대한 수요를 촉진하고 있습니다. 그러나 치료법이 없고 치료 비용이 높기 때문에 예측 기간 동안 북미 림프부종 치료 시장 성장이 방해받을 수 있습니다.

Data Bridge Market Research에 따르면 북미 림프부종 치료 시장은 2022년부터 2029년까지의 예측 기간 동안 연평균 성장률 9.7%로 성장할 것으로 예상됩니다.

Market Definition

Lymphedema refers to tissue swelling caused by an accumulation of protein-rich fluid usually drained through the body's lymphatic system. It most commonly affects the arms or legs but can also occur in the chest wall, abdomen, neck, and genitals.

Lymph nodes are an important part of your lymphatic system. Lymphedema can be caused by cancer treatments that remove or damage your lymph nodes. Any problem that blocks the drainage of lymph fluid can cause lymphedema.

Treatment may include compression bandages, massage, compression stockings, sequential pneumatic pumping, careful skincare, and surgery to remove swollen tissue or create new drainage routes.

The high prevalence of cancers, increasing innovations and technologies and rising number of players in the market, and novel product launches also propel the market's growth.

North America Lymphedema Treatment Market Dynamics

Drivers

• Rise in the number of Lymphedema Cases

The collection of lymph fluid in fatty tissues close beneath the skin is called lymphedema. The ailment is caused by a person's poor lymphatic system flow, and it manifests itself in the legs, arms, or both. Primary lymphedema affects one to two million persons in the United States, while secondary lymphedema affects two to three million.

• Increase in the Prevalence of Cancers

According to the National Cancer Institute, 1,806,590 new cancer cases will be identified in the United States in 2020, with 606,520 people dying from the disease.

According to the American Cancer Society, Inc, cancer is the main cause of death in Canada and the second-highest cause in the United States, behind heart disease. In 2018, it was anticipated that 1.9 million new cancer cases and 693,000 cancer deaths would occur in North America.

Furthermore, an increasing number of healthcare facilities and multiple therapies are the factors that will expand the lymphedema treatment market.  Additionally, the healthcare system requires highly advanced treatment products. Therefore, major players are highly focused on new and innovative product launches and approvals to drive the North America lymphedema treatment market. 

Opportunities

• Drug Approvals

The market has witnessed numerous drug approvals in past years, driven by the increasing fatality rate of disease. Increasing drug approvals will ramp up the demand for the lymphedema treatment market.

In July 2015, Siltuximab was the first drug to be approved to treat multicentric castleman's disease under the FDA priority review program in the US. The multicentric castleman's disease enlarges the lymph nodes with characteristic findings in multiple lymph node regions.

Moreover, partnerships and agreements by major players in North America will boost new opportunities for the market's growth rate.

Restraints/Challenges

However, the high cost of treatment and lack of awareness about lymphedema restrains the market. Furthermore, no permanent cure for lymphedema and difficult reimbursement act as the challenge for the North America lymphedema treatment market

North America lymphedema treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market, contact Data Bridge Market Research for an Analyst Brief; our team will help you make an informed market decision to achieve market growth.

COVID-19 Impact on North America Lymphedema Treatment Market

COVID-19 has positively affected the market. On March 11, 2020, COVID-19 was formally declared a pandemic. The COVID-19 pandemic has resulted in an unprecedented demand for healthcare resources since then.

The treatment of both primary and secondary lymphedema patients has been interrupted or delayed during COVID 19. There was a huge decrease in the number of patients visiting hospitals, which impacted the overall growth of the North America lymphedema treatment market. The COVID-19 impact has negatively affected the price of lymphedema treatment products because of the increased cost of drugs and medication prescribed for lymphedema and fewer doctor visits during the lockdown period.

According to United Nations Office on Drugs and Crime (UNODC), mobility restrictions, closed borders, and a decline in overall world trade during COVID-19 disrupted the supply chains of drug markets.

Moreover, many drugs are being produced at different locations, and due to the restrictions on movement, there has been a shortage in the drug supply. Therefore, COVID-19 has a negative impact on the supply chain of the North America lymphedema treatment market.

Recent Developments

• In February 2020, Avet Pharmaceuticals Inc. announced that they acquired a portfolio of 23 abbreviated new drug applications (ANDAs), covering 17 product families, all previously approved by the U.S. Food and Drug Administration (FDA). This broadened the product portfolio of the company
• In September 2021, Tactile Medical announced the enrollment of the first patient in a randomized, controlled clinical trial evaluating the effectiveness of Flexitouch plus for the treatment of head and neck lymphedema. This will increase the credibility of the company in the market

North America Lymphedema Treatment Market Scope

North America lymphedema treatment market is segmented based on treatment type, type, affected area, age group, route of administration, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

• Compression Therapy
• Surgery
• Drug Therapy
• Laser Therapy
• Others

On the basis of treatment type, the North America lymphedema treatment market is segmented into compression therapy, surgery, drug therapy, laser therapy, and others.

Type

• Secondary Lymphedema
• Primary Lymphedema

On the basis of type, the North America lymphedema treatment market is segmented into secondary lymphedema and primary lymphedema.

Affected Area

• Lower Extremity
• Upper Extremity
• Genitalia

On the basis of affected area, the North America lymphedema treatment market is segmented into lower extremity, upper extremity, and genitalia

Age Group

• Adult
• Geriatric
• Pediatric

On the basis of age group, the North America lymphedema treatment market is segmented into adult, geriatric, and pediatric.

Route of Administration

• Oral
• Injectable
• Topical

On the basis of route of administration, the North America lymphedema treatment market is segmented into oral, injectable, and topical.

End User

• Hospital
• Speciality Clinics
• Ambulatory Surgical Centers
• Others

Based on end user, the North America lymphedema treatment market is segmented into hospital, speciality clinics, ambulatory surgical centers, and others.

Distribution Channel

• Pharmacy Stores
• Direct Tender
• Others

Based on distribution channel, the North America lymphedema treatment market is segmented into pharmacy stores, direct tender, and others.

North America Lymphedema Treatment Market Regional Analysis/Insights

North America lymphedema treatment market is analyzed, and market size insights and trends are provided by country, treatment type, type, affected area, age group, route of administration, end user, and distribution channel as referenced above.

The countries covered in the North America lymphedema treatment market report are the U.S., Canada, and Mexico.

U.S. is expected to dominate the North America lymphedema treatment market due to the strong presence of market players and the rising prevalence of lymphedema diseases.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North American brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels is considered while providing forecast analysis of the country data.

Competitive Landscape and North America Lymphedema Treatment Market Share Analysis

North America lymphedema treatment market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North American presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points are only related to the companies' focus on the North America lymphedema treatment market.

Some of the major players operating in the North America lymphedema treatment market are Tactile Medical, BIOCOMPRESSION SYSTEMS, Lohmann & Rauscher GmbH & Co. KG, ThermoTek, Essity (BSN medical GmbH), Cardinal Health, Smith+Nephew, Avet Pharmaceuticals Inc., KOYA MEDICAL, SIGVARIS GROUP, AIROS Medical, Inc., Tactile Medical, medi GmbH & Co. KG, PAUL HARTMANN AG, Convatec Inc., 3M, JUZO, Mego Afek ltd, Huntleigh Healthcare Limited, HERANTIS PHARMA Plc, among others.

Research Methodology

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석 및 추정됩니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용을 알아보려면 분석가 전화를 요청하거나 문의 사항을 드롭 다운하세요. DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 기본(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 이 외에도 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 회사 시장 점유율 분석, 측정 표준, 아프리카 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의 사항을 드롭하여 산업 전문가에게 문의하세요.

SKU-66841